Ralf Gutzmer

36PUBLICATIONS
152CO-AUTHORS
Gene and molecular therapyNanotoxicology, health and safetyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Aug 12, 2026
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

|Mar 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler

|Mar 14, 2026
Mycophenolate Mofetil for Treatment of Ipilimumab-Induced Colitis in Patients with Metastatic Melanoma.

Christina Naoum, Julia K Winkler, Pawel Majenka

|Feb 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Michael Weichenthal, Dirk Debus, Lisa Zimmer

|Jan 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Reinhard Dummer, Shibing Deng, Tao Xie

|Dec 11, 2025
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.

Jessica C Hassel, Lisa Zimmer, Thomas Sickmann

Pageof 6

Frequent Collaborators

12 joint publications

Dirk Schadendorf

11 joint publications

Jessica C Hassel

8 joint publications

Paolo A Ascierto

8 joint publications

Reinhard Dummer